Ondansetron (Zofran)
What studies of Ondansetron (Zofran) found
At a glance, by condition
ME/CFS: D Little or no difference
Based on the strongest evidence, the placebo trial (very low certainty): 2 findings, all D.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Ondansetron (Zofran) for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Ondansetron (Zofran) · ME/CFS is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Fatigue1 study · 33 people took Ondansetron (Zofran) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 67 people found no clear difference; a small benefit can't be ruled out.
The placebo trial67 randomised · 10 weeks · 16 mg per day, at night
No clear difference in fatigue.
The evidence is very uncertain about the effect of ondansetron (Zofran) on fatigue in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 67 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 67 randomised
- Dose
- 16 mg per day, at night
- Outcome
- CIS-fatigue Checklist Individual Strength fatigue severity subscale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- High
Daily life and health overall
Daily functioning1 study · 33 people took Ondansetron (Zofran) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 67 people found no clear difference; a small benefit can't be ruled out.
The placebo trial67 randomised · 10 weeks · 16 mg per day, at night
No clear difference in daily functioning.
The evidence is very uncertain about the effect of ondansetron (Zofran) on daily functioning in ME/CFS. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 67 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 67 randomised
- Dose
- 16 mg per day, at night
- Outcome
- SIP-8 Sickness Impact Profile-8
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects2 studies
3, increased general feeling of malaise
The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. (2010)1 patient, the only male one, dropped out on day 3 due to headaches, dizziness and daze, possibly related to study drug in this case
Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results. (2000)
Side effects studies reported2 kinds
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 2 studies |
| Trouble sleeping | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
8 to 16 mg at the start
- 2Top dose
Most often 8 mg (1 of 2 studies)
Doses across 2 studies
8 to 16 mg.
Each study’s dose, as printed
- 16 mg per day, at night The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. (2010)
- 8 mg, twice daily (morning and evening) Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results. (2000)
All papers
- The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.2010 · placebo trial · 67 randomised
Summary
The study was a randomized, placebo-controlled, double-blind clinical trial at Radboud University Nijmegen Medical Centre, The Netherlands. Sixty-seven adult patients who fulfilled the US Centers for Disease Control and Prevention criteria for chronic fatigue syndrome participated. Thirty-three patients were allocated to ondansetron and 34 to placebo. During 10 weeks, patients took either ondansetron 16 mg per day (two 8-mg tablets) or 2 placebo tablets at night. The primary outcome variables were fatigue severity on the Checklist Individual Strength fatigue severity subscale (CIS-fatigue) and functional impairment on the Sickness Impact Profile-8 (SIP-8). Secondary measures included physical activity measured with an actometer and daily observed fatigue (DOF). Analysis of covariance showed no significant differences between the ondansetron- and placebo-treated groups during the 10-week treatment period in fatigue severity and functional impairment. Posttreatment actometer activity scores and DOF scores of the ondansetron and placebo group did not differ significantly. In the placebo arm, no participants dropped out. Three patients in the ondansetron arm dropped out within the first 2 weeks; 2 patients in the ondansetron group had missing values for posttreatment measurements. The main reason for discontinuing was an increased general feeling of malaise. Four patients (3 ondansetron and 1 placebo) had complaints of constipation, and a laxative syrup was prescribed. No other important side effects were reported in either group. In both treatment groups, an equal number of 8 patients showed an improvement of more than 10 points in the CIS-fatigue severity. Authors noted they did not monitor patient compliance on a daily basis and did not assess baseline serotonin status.
- Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.2000 · compared with another group · 20 in the study · 19 with outcome data
Summary
This open-labelled study asked whether 5-HT3 receptor antagonists help chronic fatigue syndrome (CFS). It included 20 patients meeting CDC criteria; 10 received oral tropisetron 5 mg once daily and 10 received oral ondansetron 8 mg twice daily for 15 days. Fatigue and capability were measured with visual analog scales (VAS). 19 patients finished; 1 patient in the tropisetron group dropped out on day 3 due to headaches, dizziness and daze, possibly related to study drug. In the tropisetron group, 6/9 patients documented benefit on VAS fatigue and 7/9 on VAS capability; mean changes were z20.3% and z29.9%. In the ondansetron group, 8/10 documented benefit on VAS fatigue and 8/10 on VAS capability; mean changes were z27.9% and z23.7%. Score changes in responders were more pronounced in the tropisetron group. The frequency of concomitant symptoms did not differ significantly between treatment groups. Sleep disturbances increased in 1 (ondansetron) and 2 (tropisetron) patients; constipation in 2 and 3 patients. No unexpected adverse events were reported. Overall analysis of both studies showed improvement §35% in approximately one third of patients in both VAS; another third reported moderate improvement §10% to 35%; 5% rsp. 11% felt deterioration. The authors state limitations: small sample size, not double-blind, not placebo-controlled.